Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
- PMID: 27044939
- PMCID: PMC4966339
- DOI: 10.1200/JCO.2015.64.7412
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Abstract
Purpose: Hepatocellular carcinoma (HCC) incidence rates have been increasing in the United States for the past 35 years. Because HCC has a poor prognosis, quantitative forecasts could help to inform prevention and treatment strategies to reduce the incidence and burden of HCC.
Methods: Single-year HCC incident case and population data for the years 2000 to 2012 and ages 35 to 84 years were obtained from the SEER 18 Registry Database. We forecast incident HCC cases through 2030, using novel age-period-cohort models and stratifying by sex, race/ethnicity, and age. Rates are presented because absolute numbers may be influenced by population increases.
Results: Rates of HCC increased with each successive birth cohort through 1959. However, rates began to decrease with the 1960 to 1969 birth cohorts. Asians/Pacific Islanders (APIs) have had the highest HCC rates in the United States for many years, but the rates have stabilized and begun to decline in recent years. Between 2013 and 2030, rates among APIs are forecast to decline further, with estimated annual percentage changes of -1.59% among men and -2.20% among women. Thus, by 2030, Asians are forecast to have the lowest incidence rates among men, and Hispanics are forecast to have the highest rates among men (age-standardized rate, 44.2). Blacks are forecast to have the highest rate among women (age-standardized rate, 12.82).
Conclusion: Although liver cancer has long had some of the most rapidly increasing incidence rates, the decreasing rates seen among APIs, individuals younger than 65 years, and cohorts born after 1960 suggest that there will be declines in incidence of HCC in future years. Prevention efforts should be focused on individuals in the 1950 to 1959 birth cohorts, Hispanics, and blacks.
Published by the American Society of Clinical Oncology.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest are found in the article online at
Figures
Similar articles
-
Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States.J Natl Cancer Inst. 2019 Jun 1;111(6):550-556. doi: 10.1093/jnci/djy180. J Natl Cancer Inst. 2019. PMID: 30544184 Free PMC article.
-
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.Am J Gastroenterol. 2014 Apr;109(4):542-53. doi: 10.1038/ajg.2014.11. Epub 2014 Feb 11. Am J Gastroenterol. 2014. PMID: 24513805 Free PMC article.
-
Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention.Cancer. 2018 Sep 1;124(17):3551-3559. doi: 10.1002/cncr.31598. Epub 2018 Aug 16. Cancer. 2018. PMID: 30113700 Free PMC article.
-
Hepatocellular carcinoma: recent trends in the United States.Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34. doi: 10.1053/j.gastro.2004.09.013. Gastroenterology. 2004. PMID: 15508094 Review.
-
Hepatocellular carcinoma: an epidemiologic view.J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8. doi: 10.1097/00004836-200211002-00002. J Clin Gastroenterol. 2002. PMID: 12394209 Review.
Cited by
-
Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series.Clinics (Sao Paulo). 2022 Sep 7;77:100097. doi: 10.1016/j.clinsp.2022.100097. eCollection 2022. Clinics (Sao Paulo). 2022. PMID: 36088887 Free PMC article.
-
Vascularized Hepatocellular Carcinoma on a Chip to Control Chemoresistance through Cirrhosis, Inflammation and Metabolic Activity.Small Struct. 2023 Sep;4(9):2200403. doi: 10.1002/sstr.202200403. Epub 2023 Feb 17. Small Struct. 2023. PMID: 38073766 Free PMC article.
-
Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study.Cancer Med. 2024 Aug;13(16):e70065. doi: 10.1002/cam4.70065. Cancer Med. 2024. PMID: 39190576 Free PMC article.
-
Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.World J Gastroenterol. 2016 Oct 14;22(38):8584-8595. doi: 10.3748/wjg.v22.i38.8584. World J Gastroenterol. 2016. PMID: 27784971 Free PMC article.
-
Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis.Front Mol Biosci. 2021 Feb 16;7:599142. doi: 10.3389/fmolb.2020.599142. eCollection 2020. Front Mol Biosci. 2021. PMID: 33681288 Free PMC article.
References
-
- Smith BD, Morgan RL, Beckett GA, et al: Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 61:1-32, 2012. - PubMed
-
- King DE, Matheson E, Chirina S, et al. The status of baby boomers’ health in the United States: The healthiest generation? JAMA Intern Med. 2013;173:385–386. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous